» Articles » PMID: 34524562

Risk Factors for Invasive Aspergillosis in ICU Patients with COVID-19: Current Insights and New Key Elements

Overview
Specialty Critical Care
Date 2021 Sep 15
PMID 34524562
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Invasive pulmonary aspergillosis (IPA) has always been a challenging diagnosis and risk factors an important guide to investigate specific population, especially in Intensive Care Unit. Traditionally recognized risk factors for IPA have been haematological diseases or condition associated with severe immunosuppression, lately completed by chronic conditions (such as obstructive pulmonary disease, liver cirrhosis, chronic kidney disease and diabetes), influenza infection and Intensive Care Unit (ICU) admission. Recently, a new association with SARS-CoV2 infection, named COVID-19-associated pulmonary aspergillosis (CAPA), has been reported worldwide, even if its basic epidemiological characteristics have not been completely established yet. In this narrative review, we aimed to explore the potential risk factors for the development of CAPA and to evaluate whether previous host factors or therapeutic approaches used in the treatment of COVID-19 critically ill patients (such as mechanical ventilation, intensive care management, corticosteroids, broad-spectrum antibiotics, immunomodulatory agents) may impact this new diagnostic category. Reviewing all English-language articles published from December 2019 to December 2020, we identified 21 papers describing risk factors, concerning host comorbidities, ICU management, and COVID-19 therapies. Although limited by the quality of the available literature, data seem to confirm the role of previous host risk factors, especially respiratory diseases. However, the attention is shifting from patients' related risk factors to factors characterizing the hospital and intensive care course, deeply influenced by specific features of COVID treatment itself. Prolonged invasive or non-invasive respiratory support, as well as the impact of corticosteroids and/or immunobiological therapies seem to play a pivotal role. ICU setting related factors, such as environmental factors, isolation conditions, ventilation systems, building renovation works, and temporal spread with respect to pandemic waves, need to be considered. Large, prospective studies based on new risk factors specific for CAPA are warranted to guide surveillance and decision of when and how to treat this particular population.

Citing Articles

Pneumonia in Transplant Recipients: A Comprehensive Review of Diagnosis and Management.

Pata R, Kristeva J, Kosuru B Cureus. 2024; 16(11):e73669.

PMID: 39544950 PMC: 11562015. DOI: 10.7759/cureus.73669.


Invasive pulmonary aspergillosis among patients with severe community-acquired pneumonia and influenza in ICUs: a retrospective cohort study.

Lee W, Chang C, Ho M, Lin C, Leu S, Lin C Pneumonia (Nathan). 2024; 16(1):10.

PMID: 38790032 PMC: 11127357. DOI: 10.1186/s41479-024-00129-9.


Clinical characteristics, diagnosis, treatment, and outcome of patients with liver abscess due to Aspergillus spp: a systematic review of published cases.

Dumic I, Caetano E, Domingues S, Pantic I, Radovanovic M, Rueda Prada L BMC Infect Dis. 2024; 24(1):345.

PMID: 38519916 PMC: 10960385. DOI: 10.1186/s12879-024-09226-y.


Epidemiology and antifungal susceptibilities of clinically isolated species in South China.

Bilal H, Zhang D, Shafiq M, Khan M, Chen C, Khan S Epidemiol Infect. 2023; 151:e184.

PMID: 37846567 PMC: 10644062. DOI: 10.1017/S095026882300167X.


Missed Opportunities for Antifungal Stewardship during the COVID-19 Era.

Hawkins B, Walker S, Shorman M Antibiotics (Basel). 2023; 12(9).

PMID: 37760649 PMC: 10526074. DOI: 10.3390/antibiotics12091352.


References
1.
Koehler P, Bassetti M, Chakrabarti A, Chen S, Colombo A, Hoenigl M . Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2020; 21(6):e149-e162. PMC: 7833078. DOI: 10.1016/S1473-3099(20)30847-1. View

2.
Arkel A, Rijpstra T, Belderbos H, van Wijngaarden P, Verweij P, Bentvelsen R . COVID-19-associated Pulmonary Aspergillosis. Am J Respir Crit Care Med. 2020; 202(1):132-135. PMC: 7328331. DOI: 10.1164/rccm.202004-1038LE. View

3.
Mitaka H, Perlman D, Javaid W, Salomon N . Putative invasive pulmonary aspergillosis in critically ill patients with COVID-19: An observational study from New York City. Mycoses. 2020; 63(12):1368-1372. PMC: 7646269. DOI: 10.1111/myc.13185. View

4.
Pourbaix A, Lafont Rapnouil B, Guery R, Lanternier F, Lortholary O, Cohen J . Smoking as a Risk Factor of Invasive Fungal Disease: Systematic Review and Meta-Analysis. Clin Infect Dis. 2020; 71(4):1106-1119. DOI: 10.1093/cid/ciaa001. View

5.
Abdalla S, Almaslamani M, Hashim S, Ibrahim A, Omrani A . Fatal Coronavirus Disease 2019-associated Pulmonary Aspergillosis; A Report of Two Cases and Review of the Literature. IDCases. 2020; 22:e00935. PMC: 7443053. DOI: 10.1016/j.idcr.2020.e00935. View